$APTO
Aptose Biosciences Inc.

2018 Q1 Form 8-K Financial Statement

#000117184319001669 Filed on March 12, 2019

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q4 2017 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.700M $1.240M $1.580M
YoY Change 134.18% 2.48% -16.4%
% of Gross Profit
Research & Development $3.140M $2.050M $1.735M
YoY Change 80.98% 6.22% 3.27%
% of Gross Profit
Depreciation & Amortization $16.00K $10.00K $23.00K
YoY Change -30.43% -80.0% 15.0%
% of Gross Profit
Operating Expenses $6.842M $3.310M $3.325M
YoY Change 105.77% 4.42% -7.38%
Operating Profit
YoY Change
Interest Expense $30.00K $20.00K $30.00K
YoY Change 0.0% -66.67% -127.27%
% of Operating Profit
Other Income/Expense, Net $28.00K $33.00K
YoY Change -15.15%
Pretax Income -$6.820M -$3.290M -$3.290M
YoY Change 107.29% 5.79% -11.08%
Income Tax
% Of Pretax Income
Net Earnings -$6.814M -$3.270M -$3.292M
YoY Change 106.99% 5.14% -11.03%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$234.8K -$147.5K -$189.1K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q4 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.20M $11.40M $9.000M
YoY Change 80.0% 44.3% -22.41%
Cash & Equivalents $15.41M $10.63M $8.992M
Short-Term Investments $800.0K $800.0K
Other Short-Term Assets $97.00K $74.00K $300.0K
YoY Change -67.67% -85.2% -50.0%
Inventory
Prepaid Expenses $249.0K $322.0K
Receivables
Other Receivables
Total Short-Term Assets $16.52M $11.83M $9.300M
YoY Change 77.68% 40.77% -23.77%
LONG-TERM ASSETS
Property, Plant & Equipment $150.0K $142.0K $200.0K
YoY Change -25.0% -29.0% -33.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $150.0K $142.0K $200.0K
YoY Change -25.0% -29.0% -33.33%
TOTAL ASSETS
Total Short-Term Assets $16.52M $11.83M $9.300M
Total Long-Term Assets $150.0K $142.0K $200.0K
Total Assets $16.67M $11.97M $9.500M
YoY Change 75.52% 39.15% -24.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $362.0K $589.0K $1.800M
YoY Change -79.89% -54.69% 500.0%
Accrued Expenses $1.843M $1.176M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.205M $1.765M $1.800M
YoY Change 22.5% 35.77% 28.57%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.205M $1.765M $1.800M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.200M $1.800M $1.800M
YoY Change 22.22% 38.46% 28.57%
SHAREHOLDERS EQUITY
Retained Earnings -$253.6M -$246.8M
YoY Change
Common Stock $240.8M $231.9M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $14.47M $10.20M $7.773M
YoY Change
Total Liabilities & Shareholders Equity $16.67M $11.97M $9.500M
YoY Change 75.52% 39.15% -24.0%

Cashflow Statement

Concept 2018 Q1 2017 Q4 2017 Q1
OPERATING ACTIVITIES
Net Income -$6.814M -$3.270M -$3.292M
YoY Change 106.99% 5.14% -11.03%
Depreciation, Depletion And Amortization $16.00K $10.00K $23.00K
YoY Change -30.43% -80.0% 15.0%
Cash From Operating Activities -$4.054M -$2.840M -$2.645M
YoY Change 53.27% -4.38% -19.85%
INVESTING ACTIVITIES
Capital Expenditures $24.00K -$10.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $2.150M $10.00K
YoY Change 1164.71%
Cash From Investing Activities -$24.00K $2.140M
YoY Change 1158.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.855M 3.520M 3.676M
YoY Change 140.89% 5.39%
NET CHANGE
Cash From Operating Activities -4.054M -2.840M -2.645M
Cash From Investing Activities -24.00K 2.140M
Cash From Financing Activities 8.855M 3.520M 3.676M
Net Change In Cash 4.777M 2.820M 1.052M
YoY Change 354.09% 422.22% -131.88%
FREE CASH FLOW
Cash From Operating Activities -$4.054M -$2.840M -$2.645M
Capital Expenditures $24.00K -$10.00K
Free Cash Flow -$4.078M -$2.830M -$2.645M
YoY Change 54.18% -4.71% -19.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 apto Research And Development Liabilities Current
ResearchAndDevelopmentLiabilitiesCurrent
960000
CY2017Q4 apto Research And Development Liabilities Current
ResearchAndDevelopmentLiabilitiesCurrent
176000
CY2018Q1 apto Sharebased Compensation Arrangement By Sharebased Payment Award Maximum Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares
5300000
CY2018Q1 apto Sharebased Compensation Arrangement By Sharebased Payment Award Maximum Subscription Rate
SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumSubscriptionRate
0.175
CY2018Q1 apto Time Deposits Gross
TimeDepositsGross
790000
CY2017Q4 apto Time Deposits Gross
TimeDepositsGross
816000
CY2018Q1 apto Time Deposits Unrealized Loss
TimeDepositsUnrealizedLoss
20000
CY2017Q4 apto Time Deposits Unrealized Loss
TimeDepositsUnrealizedLoss
18000
CY2017Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
61000
CY2018Q1 us-gaap Assets
Assets
16674000
CY2017Q4 us-gaap Assets
Assets
11967000
CY2018Q1 us-gaap Assets Current
AssetsCurrent
16524000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
11825000
CY2018Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
150000
CY2017Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
142000
CY2018Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
362000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
589000
CY2018Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1843000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1176000
CY2018Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4318000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4316000
CY2018Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
31593000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
29365000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2228000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2228000
CY2018Q1 us-gaap Basis Of Accounting
BasisOfAccounting
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 0"></td> <td style="width: 0.5in"><div style="display: inline; color: #010000"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.</div></div></td> <td style="text-align: justify">Comparative figures:</td> </tr> </table> <div style=" margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in"></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in">Certain comparative figures in the periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2017, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> have been reclassified in order to conform to US GAAP. On the statement of financial position, prepaid expenses and other current assets were previously presented on the statement of on a combined basis, as were account payables and accrued liabilities. Paid in capital was previously presented on the statement of financial position as Contributed Surplus and Stock options. On the statement of loss and comprehensive loss, foreign exchange gains and losses on marketable securities that were previously recorded in other income and expenses were reclassified to other comprehensive income.</div></div>
CY2018Q1 us-gaap Cash
Cash
1169000
CY2017Q4 us-gaap Cash
Cash
3225000
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15408000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10631000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10631000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7940000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15408000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8992000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4777000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1052000
CY2018Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
14239000
CY2017Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
7406000
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2018Q1 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2017 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30702053
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27502053
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30702053
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27502053
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
240778000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
231923000
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6816000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3292000
CY2018Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"><tr style="vertical-align: top"><td style="width: 0.5in"></td> <td style="width: 0.25in"><div style="display: inline; color: #010000">(g)</div></td> <td style="text-align: justify">Concentration of risk</td> </tr> </table> <div style=" margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</div> <div style=" margin: 0pt 0 0pt 0.75in; font-size: 10pt; text-align: justify; text-indent: 0in"></div> <div style=" margin: 0pt 0 0pt 0.75in; font-size: 10pt; text-align: justify; text-indent: 0in">The Company is subject to credit risk from the Company&#x2019;s cash and cash equivalents and investments. The carrying amount of the financial assets represents the maximum credit exposure. The Company manages credit risk associated with its cash and cash equivalents and investments by maintaining minimum standards of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">R1</div>-low or A-low investments and the Company invests only in highly rated Canadian corporations which are capable of prompt liquidation.</div></div></div></div></div></div></div></div></div></div>
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
16000
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
23000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2018Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
CY2017Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
21000
CY2018Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
266000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
734000
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y306D
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2360000
CY2018Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
207000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-227000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
273000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
667000
CY2018Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-26000
CY2017Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
21000
CY2018Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-16000
CY2017Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3702000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1590000
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
168000
CY2018Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
23000
CY2017Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-29000
CY2018Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-73000
CY2017Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-114000
CY2018Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
44000
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
33000
CY2018Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
268000
CY2018Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1387000
CY2018Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
78000
CY2018Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
276000
CY2018Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
281000
CY2018Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
277000
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16674000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11967000
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2205000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1765000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8855000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3676000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4054000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2645000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-6814000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-3292000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
28000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
33000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
6842000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
3325000
CY2018Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
617000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
266000
CY2018Q1 us-gaap Other Assets Current
OtherAssetsCurrent
97000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
74000
CY2018Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-2000
CY2017Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2000
CY2018Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
5000
CY2017Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
21000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
CY2018Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
249000
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
322000
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
150000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
142000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3140000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1735000
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-253584000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-246770000
CY2018Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
CY2017Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.85
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2344000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4403000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.011
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2453000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.63
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2059000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.14
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2228000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
61000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.939
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.013
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0239
CY2017Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
61000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
14469000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
10202000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
7328000
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
7773000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.46
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.18
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.96
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y292D
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y182D
CY2018Q1 us-gaap Short Term Investments
ShortTermInvestments
770000
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
798000
CY2018Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8855000
CY2017Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3676000
CY2018Q1 us-gaap Time Deposits At Carrying Value
TimeDepositsAtCarryingValue
770000
CY2017Q4 us-gaap Time Deposits At Carrying Value
TimeDepositsAtCarryingValue
798000
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"><tr style="vertical-align: top"><td style="width: 0.5in"></td> <td style="width: 0.25in"><div style="display: inline; color: #010000">(c)</div></td> <td style="text-align: justify">Significant accounting policies, estimates and judgments:</td> </tr> </table> <div style=" margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.75in">The preparation of these consolidated financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of revenue and expenses during the reporting period. Actual outcomes could differ from those estimates. The consolidated financial statements include estimates, which, by their nature, are uncertain.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.75in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.75in">The impacts of such estimates are pervasive throughout the consolidated financial statements and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>require accounting adjustments based on future occurrences.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.75in">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.75in">The estimates and underlying assumptions are reviewed on a regular basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected.</div></div></div></div></div></div></div></div></div></div>
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29042000
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17399000

Files In Submission

Name View Source Status
0001171843-19-001669-index-headers.html Edgar Link pending
0001171843-19-001669-index.html Edgar Link pending
0001171843-19-001669.txt Edgar Link pending
0001171843-19-001669-xbrl.zip Edgar Link pending
apto-20180331.xml Edgar Link completed
apto-20180331.xsd Edgar Link pending
apto-20180331_cal.xml Edgar Link unprocessable
apto-20180331_def.xml Edgar Link unprocessable
apto-20180331_lab.xml Edgar Link unprocessable
apto-20180331_pre.xml Edgar Link unprocessable
exh_991.htm Edgar Link pending
f8k_031219.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
logo.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending